Home›Trial›NCT07421739

🔬NCT07421739RECRUITING

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Study Summary

To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.

Conditions

Choroidal Melanoma Indeterminate Lesions Uveal Melanoma Ocular Melanoma

Interventions / Drugs

Non-interventional, digital, patient-reported, real-world study

View on ClinicalTrials.gov ↗

Sponsor

Aura Biosciences

Ocular Oncology

Study Details

Enrollment15 participants

Primary Completion—

Lead SponsorAura Biosciences

Data Retrieved2026-04-11 02:55:09.188953+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.